Emory University acquired a new position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 34,143 shares of the biopharmaceutical company’s stock, valued at approximately $2,738,000. Loxo Oncology comprises 2.4% of Emory University’s holdings, making the stock its 2nd biggest position. Emory University owned about 0.13% of Loxo Oncology at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of LOXO. Teachers Advisors LLC grew its stake in Loxo Oncology by 4.3% during the 4th quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the last quarter. Nationwide Fund Advisors grew its stake in Loxo Oncology by 31.9% during the 1st quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 6,632 shares during the last quarter. Wells Fargo & Company MN grew its stake in Loxo Oncology by 33.3% during the 1st quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Loxo Oncology by 92.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 9,200 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Loxo Oncology by 41.8% during the 1st quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock worth $4,310,000 after buying an additional 30,210 shares during the last quarter.

Shares of Loxo Oncology, Inc. (LOXO) traded up 3.07% during mid-day trading on Thursday, hitting $89.25. The stock had a trading volume of 368,006 shares. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $89.44. The firm’s 50-day moving average price is $74.92 and its 200 day moving average price is $60.43. The stock’s market cap is $2.66 billion.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the previous year, the business earned ($0.77) earnings per share. Equities analysts forecast that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

A number of brokerages recently commented on LOXO. BidaskClub downgraded Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BTIG Research reiterated a “buy” rating and set a $75.00 price target on shares of Loxo Oncology in a research report on Thursday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and set a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Loxo Oncology in a research report on Monday, June 5th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $70.73.

TRADEMARK VIOLATION NOTICE: “Emory University Invests $2.74 Million in Loxo Oncology, Inc. (LOXO) Stock” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/14/emory-university-invests-2-74-million-in-loxo-oncology-inc-loxo-stock.html.

In related news, insider Naarden Jacob Van sold 3,082 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $73.57, for a total transaction of $226,742.74. Following the completion of the sale, the insider now directly owns 1,541 shares of the company’s stock, valued at approximately $113,371.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jennifer Burstein sold 1,700 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $73.73, for a total value of $125,341.00. Following the sale, the vice president now directly owns 1,700 shares of the company’s stock, valued at $125,341. The disclosure for this sale can be found here. Insiders have sold a total of 46,073 shares of company stock valued at $3,397,662 over the last ninety days. Insiders own 44.40% of the company’s stock.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.